Gradishar W - Search Results

1

Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens.

Moy B, Oliveira M, Saura C, Gradishar W, Kim SB, Brufsky A, Hurvitz SA, Ryvo L, Fagnani D, Kalmadi S, Silverman P, Delaloge S, Alarcon J, Kwong A, Lee KS, Ang PCS, Ow SGW, Chu SC, Bryce R, Keyvanjah K, Bebchuk J, Zhang B, Oestreicher N, Bose R, Chan N. Moy B, et al. Among authors: gradishar w. Breast Cancer Res Treat. 2021 Jul;188(2):449-458. doi: 10.1007/s10549-021-06217-4. Epub 2021 Apr 28. Breast Cancer Res Treat. 2021. PMID: 33909203 Free PMC article. Clinical Trial.

2

Chemotherapy-related hemolytic-uremic syndrome after the treatment of head and neck cancer. A case report.

Gradishar WJ, Vokes EE, Ni K, Panje WR. Gradishar WJ, et al. Cancer. 1990 Nov 1;66(9):1914-8. doi: 10.1002/1097-0142(19901101)66:9<1914::aid-cncr2820660910>3.0.co;2-g. Cancer. 1990. PMID: 2224786

3

Effects of high dose raloxifene in selected patients with advanced breast carcinoma.

Gradishar W, Glusman J, Lu Y, Vogel C, Cohen FJ, Sledge GW Jr. Gradishar W, et al. Cancer. 2000 May 1;88(9):2047-53. doi: 10.1002/(sici)1097-0142(20000501)88:9<2047::aid-cncr10>3.0.co;2-e. Cancer. 2000. PMID: 10813716

4

Clinical status of capecitabine in the treatment of breast cancer.

Gradishar WJ. Gradishar WJ. Oncology (Williston Park). 2001 Jan;15(1 Suppl 2):69-71; discussion 72. Oncology (Williston Park). 2001. PMID: 11219981 Free article. Review.

5

A rationale for the reinitiation of adjuvant tamoxifen therapy in women receiving fewer than 5 years of therapy.

Gradishar WJ, Hellmund R. Gradishar WJ, et al. Clin Breast Cancer. 2002 Jan;2(4):282-6. doi: 10.3816/cbc.2002.n.003. Clin Breast Cancer. 2002. PMID: 11899359 Review.

6

Primary (neoadjuvant) chemotherapy with docetaxel in breast cancer.

Gradishar WJ. Gradishar WJ. Clin Breast Cancer. 2001 Oct;2 Suppl 1:S31-5. doi: 10.3816/cbc.2001.s.005. Clin Breast Cancer. 2001. PMID: 11970742 Review.

7

Role of capecitabine (Xeloda) in breast cancer.

Kaklamani VG, Gradishar WJ. Kaklamani VG, et al. Expert Rev Anticancer Ther. 2003 Apr;3(2):137-44. doi: 10.1586/14737140.3.2.137. Expert Rev Anticancer Ther. 2003. PMID: 12722873 Review.

8

Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?

Kaklamani VG, Gradishar WJ. Kaklamani VG, et al. Clin Breast Cancer. 2003 Apr;4 Suppl 1:S26-33. doi: 10.3816/cbc.2003.s.012. Clin Breast Cancer. 2003. PMID: 12756076 Review.

9

Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study.

Gradishar WJ, Meza LA, Amin B, Samid D, Hill T, Chen YM, Lower EE, Marcom PK. Gradishar WJ, et al. J Clin Oncol. 2004 Jun 15;22(12):2321-7. doi: 10.1200/JCO.2004.12.128. J Clin Oncol. 2004. PMID: 15197193 Clinical Trial.

10

Implications of first-line adjuvant treatment with aromatase inhibitors in recurrent metastatic breast cancer.

Sokolowicz LE, Gradishar WJ. Sokolowicz LE, et al. Clin Breast Cancer. 2004 Sep;5 Suppl 1:S24-30. doi: 10.3816/cbc.2004.s.011. Clin Breast Cancer. 2004. PMID: 15347436 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

324 results

Search Page

Filters